This is a prospective, single-arm, open-label study to evaluate the safety and efficacy of
Xiongdan Wan monotherapy in patients with Major Depressive Disorder(MDD), conducted in Shang
Hai Mental Health Center. Following a screening period, subjects who meet the entry criteria
will be treated with 450mg Xiongdan Wan pills three times daily for 8 weeks.